SLC6A20 ASO Restores Brain Signaling in Autism Mice
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eunjoon Kim and the IBS Center for Synaptic Brain Dysfunctions found that reducing activity of the glycine transporter Slc6a20a restored NMDA receptor function, a signaling pathway linked to autism, schizophrenia, and intellectual disability.
- Antisense oligonucleotides (ASOs) targeting Slc6a20a were tested in mice carrying mutations in the autism risk genes SHANK2 and SHANK3, and improved social interaction, social communication, and repetitive behaviors.
- The treatment worked in adult mice, suggesting that NMDAR dysfunction may remain treatable after major stages of brain development are complete — a finding the researchers flagged as notable.
- A single ASO dose remained effective for at least 8 weeks in treated mice, with no detectable adverse effects during that period, according to the study.
- The therapy worked by correcting abnormal phosphorylation patterns in proteins that regulate synaptic signaling, rather than changing total protein amounts, based on large-scale phospho-proteomic analyses.
- Human cortical organoids with CRISPR-introduced SHANK2 or SHANK3 mutations showed reduced NMDAR activity that was restored to near-normal levels after treatment with a human-targeted SLC6A20 ASO.
- The study was published in Nature Communications (2026) and identifies SLC6A20 as a more brain-region-specific alternative to GlyT1, whose prior targeting had been limited by effects on brainstem-controlled breathing and movement.
Why it matters: For autism drug development, which has been stalled by failed trials of earlier glycine-based NMDAR boosters, this study offers a new, more spatially restricted target — and the adult-mouse response challenges the assumption that NMDAR-related deficits can only be corrected early in brain development. If the SLC6A20 approach holds up beyond organoids, it could eventually serve a broader group of NMDAR-hypofunction disorders beyond autism, including schizophrenia.
